Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:01 ET
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results
February 21, 2023 07:00 ET
|
Assertio Holdings, Inc.
Year-over-Year Net Product Sales Increased at Least 54% for the Fourth Quarter and 41% for the Full Year Cash Flows from Operations Was at Least $26 Million for the Fourth Quarter and $78 Million for...
Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference
February 08, 2023 08:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
January 17, 2023 09:00 ET
|
Assertio Holdings, Inc.
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
January 09, 2023 16:15 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2023 16:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco
December 13, 2022 14:07 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
December 05, 2022 07:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Third Quarter 2022 Financial Results
November 08, 2022 16:01 ET
|
Assertio Holdings, Inc.
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36%Increases Guidance for Net Product Sales and Adjusted EBITDADebt Refinancing Extends Maturity, Reduces Cost and...
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 27, 2022 16:05 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...